A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)

Phase 4

• Conditions: Moderate to Severe Dry Eye
• Interventions: Drug: Cyclosporine 0.1% (Ikervis®) eye drop

• Registration Number: NCT04775303
• Lead Sponsor: Yonsei University

Brief Summary

A clinical trial to evaluate the efficacy and safety of Cyclosporine 0.1% (Ikervis®) for moderate to severe dry eye patients who changed to Cyclosporine 0.1% eye drop(Ikervis®) due to lack of treatment effects of the previous Cyclosporine 0.05% eye drop.

Detailed Description

Eligible patients who agree to participate in the clinical trial in writing will be administered Cyclosporine 0.1% eye drop(Ikervis®) one drop once daily for 12 weeks. Efficacy and safety will be evaluated at baseline, 4 weeks, 8 weeks, and 12 weeks.

Study Timeline

• Study Start: 2020-09-25
• Status Verified: 2021-02
• Study First Submitted: 2021-02-25
• Study First Submitted QC: 2021-02-25
• Last Update Submitted: 2021-02-25
• Study First Posted: 2021-03-01
• Last Update Posted: 2021-03-01
• Primary Completion: 2022-01
• Study Completion: 2022-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

1. Age between 19 and less than 80 years old

2. A patient with moderate or severe dry eye who has used Cyclosporine 0.05% eye drop for more than 3 months and has no or insufficient treatment effect

   • No or insufficient treatment effect should meet the following criteria through tests used to diagnose dry eyes
   • A SANDE (Symptom Assessment in Dry Eye) score of 40 or more on the severity and frequency of dry eye symptoms.
   • Cornea staining score (NEI scale) 3 or more points
   • Tear Break Up Time(TBUT) 10 seconds or less
   • Tear volume tested by Tear Meniscometry less than 5mm
   • Has One or more of the dry eye symptoms; stinging, irritating, itching or blurred vision.
   • Use of diquafosol tetrasodium 3% eye drop and/or artificial tears are allowed with no change of products and dosage throughout the trial period

3. A person who voluntarily agrees in writing to participate in this clinical trial

Exclusion Criteria

1. Use of eye drops within four weeks of the consent date such as steroids, glaucoma, allergies and anti-inflammatory drugs, etc.
2. Systematic steroid within four weeks of the consent date
3. Patients with pterygium
4. Start new immunosuppressive drugs or change in dosage that can affect immune function within four weeks of the consent date due to an unregulated systemic disease.
5. Severe MGD patient
6. Ophthalmic surgery (including Lasik/Lasek) and trauma in eyes within the last three months
7. Wearing contact lenses during a clinical trial period
8. Planning an eye surgery (including Lasik/Lasek) during the clinical trial period
9. Hypersensitivity to the clinical trial drug
10. Active or suspected eye infections
11. Pregnant or breastfeeding, or women planning to become pregnant
12. Participation in other clinical trials within three months
13. Any person who is deemed unfit for clinical trial by a investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
experimental group	Cyclosporine 0.1% (Ikervis®) eye drop	Cyclosporine 0.1% (Ikervis®) eye drop - one drop once daily

Primary Outcome Measures

Name	Time	Method
Cornea staining score (NEI scale)	12 weeks	The cornea staining score(NEI scale) is a grading scale for the corneal surface after fluorescein staining to help measure the efficacy of dry eye treatment. A standardized grading system of 0 to 3 is used for each of the five areas on each cornea. Grade 0 is specified when no staining is present, and the maximum score is 15.

Secondary Outcome Measures

Name	Time	Method
SANDE(Symptom Assessment in Dry Eye) score	4 weeks, 8 weeks, 12 weeks	SANDE (Symptom Assessment in Dry Eye)is a short questionnaire that quantifies both severity and frequency of dry eye symptoms
Ratio of patients who have improvement, deterioration, and no-change of cornea staining scores(NEI scale)	4 weeks, 8 weeks, 12 weeks	Cornea staining scores (NEI scale) (Improvement: decrease by more than one point / Deterioration : increase by more than one point / No change: no change in score)
Conjunctival staining scores (NEI scale)	4 weeks, 8 weeks, 12 weeks	The conjunctival staining score(NEI scale) is a grading scale for the conjunctival surface after fluorescein staining to help measure the efficacy of dry eye treatment. A standardized grading system of 0 to 3 is used for each of the six areas on each conjunctiva. Grade 0 is specified when no staining is present, and the maximum score is 18.
ODS (Ocular Discomfort Scale)	4 weeks, 8 weeks, 12 weeks	A simple questionnaire to evaluation the dry eye symptom of stinging, irritation, itching, and blurred vision.(0 to 10 points)
Patient Reported Outcome (PRO)	12 weeks	A short questionnaire to evaluation the improvement of dry eye symptom by a patient.
Tear Break-Up Time (TBUT)	4 weeks, 8 weeks, 12 weeks	Tear Break-Up Time(TBUT) is a clinical test used to evaluate the dry eye disease after the fluorescein is instilled into the patient's tear film.
Tear Meniscometry score	4 weeks, 8 weeks, 12 weeks	A simple method of quantification of the volume of tear meniscus in the diagnosis of the dry eye syndromes.

Trial Locations

Locations (1)

Severance Hospital; 🇰🇷 Seoul, Korea, Republic of